Pharmaceutical Industry

Infectious Diseases Healthcare Access Company Valuation Chronic Diseases Immunology Policy Proposals Oncology Access to Medicine Federal Funding Health Funding

FDA Approves Yeztugo, First Twice-Yearly Shot Preventing HIV

Gilead’s list price of $28,218 draws criticism from advocates urging lower costs to extend availability to poorer nations.

Stories older than 24h

FDA Launches National Priority Voucher Program to Slash Drug Review Times

RFK Jr. Weighs New Limits on TV Drug Advertising

All States Sign Off on $7.4 Billion Purdue Pharma Opioid Settlement

Sanders and King Introduce Bill to Ban Direct-to-Consumer Prescription Drug Ads

FDA Introduces Elsa AI to Fast-Track Drug and Device Approvals

FDA Approves Merck’s Enflonsia Monoclonal Antibody for Infant RSV Prevention

HHS Withdraws $766 Million for Moderna’s Bird Flu mRNA Vaccine

U.S. Cancels Moderna’s $600 Million Bird Flu Vaccine Contract

FDA Approves Moderna’s mNEXSPIKE for High-Risk Populations

Arvinas’ Vepdegestrant Delays Breast Cancer Progression Longer Than Faslodex

HHS Withdraws $766 Million From Moderna’s Bird Flu Vaccine Program

Mixed Phase 3 Outcomes Cloud Future of Regeneron and Sanofi’s COPD Candidate Itepekimab

Kennedy Advances MAHA Health Overhaul Despite Report Critiques

FDA Halts Rocket’s RP-A501 Gene Therapy for Danon Disease After Patient’s Death

FDA Ends GLP-1 Drug Shortages, Triggering New Pricing and Coverage Moves

U.S. Drug Launch Prices Skyrocket, Driven by Rare Disease Treatments

Moderna Withdraws Flu-COVID Vaccine Application After FDA Requests More Data

Trump Orders U.S. Drug Prices Tied to Lowest OECD Rates, Sparking Concerns Over Global Impact

Trump's Executive Order Enacts Global Benchmark for U.S. Drug Prices